Peter L. Anderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter L. Anderson has a total of 487 co-authors. Here are the top co-authors by number of shared publications:
Lane R. Bushman
Department of Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA
19 shared publications- Jose Ramon Castillo-Mancilla
Division of Infectious Diseases, School of Medicine, University of Colorado-AMC, Aurora, Colorado, USA
14 shared publications Jia-Hua Zheng
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado
12 shared publicationsSamantha MaWhinney
Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus , Aurora, Colorado
11 shared publicationsEdward M. Gardner
Denver Health Medical Center, Denver, Colorado, USA
9 shared publicationsJennifer J. Kiser
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
9 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
A Novel Injectable Drug Combination Nanoparticle Containing 3 Antiretrovirals Designed for Human Immunodeficiency Virus Treatment: A First-in-Human Trial
Background: Long-acting antiretroviral therapy may improve adherence and decrease stigma, yet affordable combination formulations for global usage are lacking. The TLC-ART program engineered an injectable 3-drug combination in a novel nanoparticle (DcNP) product “TLC-ART 101,” composed of lopinavir (LPV), ritonavir (RTV), and tenofovir (TVF) and 2 lipid excipients. We report safety and pharmacokinetics from this first-in-human study. Methods: Three dose cohorts of people without human immunodeficiency virus (HIV) received a single subcutaneous dose of 1.5, 3.0, or 4.0 mL in an adaptive trial of up to 64 days. LPV, RTV, and TFV were measured over time in plasma, peripheral blood mononuclear cells (PBMCs), and lymph nodes. Results: All 12 participants completed the study. One participant experienced anaphylaxis, and 4 had nonserious hypersensitivity events (rash, lip swelling, generalized pruritus). All participants had grade 1–2 injection-site reactions. At the highest dose, median LPV half-life (T1/2) was 17 days, and LPV was detectable through 2 months in most participants. RTV T1/2 was 12 hours. Plasma TFV T1/2 was 3.5 days; TFV diphosphate was detected intracellularly through 14 days. Total exposure (area under the curve) was higher in PBMCs versus plasma for all 3 drugs. Conclusions: The first human application of this novel HIV DcNP resulted in detection of LPV through 2 months and TFV up to 4 days in plasma, and no meaningful prolongation of RTV. Systemic hypersensitivity was common, and although IgE elevation was not observed, additional mechanistic understanding is required prior to further development of this DcNP pipeline. Clinical Trials Registration: NCT05850728.
- 23 October 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Open AccessA Novel Injectable Drug Combination Nanoparticle Containing 3 Antiretrovirals Designed for Human Immunodeficiency Virus Treatment: A First-in-Human Trial
Background: Long-acting antiretroviral therapy may improve adherence and decrease stigma, yet affordable combination formulations for global usage are lacking. The TLC-ART program engineered an injectable 3-drug combination in a novel nanoparticle (DcNP) product “TLC-ART 101,” composed of lopinavir (LPV), ritonavir (RTV), and tenofovir (TVF) and 2 lipid excipients. We report safety and pharmacokinetics from this first-in-human study. Methods: Three dose cohorts of people without human immunodeficiency virus (HIV) received a single subcutaneous dose of 1.5, 3.0, or 4.0 mL in an adaptive trial of up to 64 days. LPV, RTV, and TFV were measured over time in plasma, peripheral blood mononuclear cells (PBMCs), and lymph nodes. Results: All 12 participants completed the study. One participant experienced anaphylaxis, and 4 had nonserious hypersensitivity events (rash, lip swelling, generalized pruritus). All participants had grade 1–2 injection-site reactions. At the highest dose, median LPV half-life (T1/2) was 17 days, and LPV was detectable through 2 months in most participants. RTV T1/2 was 12 hours. Plasma TFV T1/2 was 3.5 days; TFV diphosphate was detected intracellularly through 14 days. Total exposure (area under the curve) was higher in PBMCs versus plasma for all 3 drugs. Conclusions: The first human application of this novel HIV DcNP resulted in detection of LPV through 2 months and TFV up to 4 days in plasma, and no meaningful prolongation of RTV. Systemic hypersensitivity was common, and although IgE elevation was not observed, additional mechanistic understanding is required prior to further development of this DcNP pipeline. Clinical Trials Registration: NCT05850728.
- Open Access
- 26 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Cephalexin Model-Informed Dosing Recommendations for Severe Infections: A Pooled Pharmacokinetic Analysis From Infancy to Adulthood
Background: Cephalexin is increasingly used as initial and oral transition therapy for severe infections, but optimal dosing in this setting remains uncertain. Methods: Four cephalexin pharmacokinetic (PK) datasets spanning preterm neonates through young adults were pooled to develop a unified population PK model. Simulations estimated probability of target attainment (PTA) and cumulative fractional response (CFR, target attainment weighted across the pathogen MIC distribution) across fT > MIC targets (free drug time above the minimum inhibitory concentration), MIC distributions for methicillin-susceptible Staphylococcus aureus (MSSA) and Enterobacterales, and multiple dosing regimens. Results: Seventy-one subjects (age 9 days–29 years) contributed 360 plasma samples, best described by a 1-compartment model with first-order absorption and lag time. Apparent volume and clearance scaled with fat-free mass, and clearance increased with postmenstrual age. Absorption was slower in neonates. Cephalexin 25 mg/kg/dose, maximum 1000 mg, every 8 hours, achieved 1-log kill targets for MSSA (PTA ≥ 98% for 35% fT > MIC at MIC = 4 mg/L); every 6-hour dosing was needed at MIC = 8 mg/L. For Enterobacterales, a 60% fT > MIC target was achieved only in infants < 2 months. However, higher-dose regimens (37.5–50 mg/kg, maximum 1500 mg, every 6 hours) achieved CFRs > 90% for 40%–50% fT > MIC targets when cefazolin MICs were ≤2 mg/L. Conclusions: Cephalexin PK varies with age but is well-captured by a unified size- and maturation-scaled model. These data support dosing within the FDA-approved range for systemic MSSA infections. Higher-dose regimens are necessary for adequate target attainment against Enterobacterales. Appropriately dosed cephalexin represents a viable option for selected severe infections, including oral transition therapy.
- 26 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Open AccessCephalexin Model-Informed Dosing Recommendations for Severe Infections: A Pooled Pharmacokinetic Analysis From Infancy to Adulthood
Background: Cephalexin is increasingly used as initial and oral transition therapy for severe infections, but optimal dosing in this setting remains uncertain. Methods: Four cephalexin pharmacokinetic (PK) datasets spanning preterm neonates through young adults were pooled to develop a unified population PK model. Simulations estimated probability of target attainment (PTA) and cumulative fractional response (CFR, target attainment weighted across the pathogen MIC distribution) across fT > MIC targets (free drug time above the minimum inhibitory concentration), MIC distributions for methicillin-susceptible Staphylococcus aureus (MSSA) and Enterobacterales, and multiple dosing regimens. Results: Seventy-one subjects (age 9 days–29 years) contributed 360 plasma samples, best described by a 1-compartment model with first-order absorption and lag time. Apparent volume and clearance scaled with fat-free mass, and clearance increased with postmenstrual age. Absorption was slower in neonates. Cephalexin 25 mg/kg/dose, maximum 1000 mg, every 8 hours, achieved 1-log kill targets for MSSA (PTA ≥ 98% for 35% fT > MIC at MIC = 4 mg/L); every 6-hour dosing was needed at MIC = 8 mg/L. For Enterobacterales, a 60% fT > MIC target was achieved only in infants < 2 months. However, higher-dose regimens (37.5–50 mg/kg, maximum 1500 mg, every 6 hours) achieved CFRs > 90% for 40%–50% fT > MIC targets when cefazolin MICs were ≤2 mg/L. Conclusions: Cephalexin PK varies with age but is well-captured by a unified size- and maturation-scaled model. These data support dosing within the FDA-approved range for systemic MSSA infections. Higher-dose regimens are necessary for adequate target attainment against Enterobacterales. Appropriately dosed cephalexin represents a viable option for selected severe infections, including oral transition therapy.
- 16 September 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
Longitudinal Performance of Self-Reported ART Adherence Compared With Tenofovir Diphosphate in Dried Blood Spots in South Africa
Background: Self-reported ART adherence is widely used in resource-limited settings but may not accurately reflect cumulative drug exposure. Few longitudinal studies in sub-Saharan Africa have directly compared self-report with pharmacologic adherence measures, specifically tenofovir diphosphate concentrations (TFV-DP) in dried blood spots (DBS). Setting: Observational cohort study conducted in four public-sector ART clinics in Cape Town, South Africa. Methods: We analyzed data from 250 adults living with HIV, followed monthly for 13 visits. Participants reported missed ART doses in the prior 30 days and provided DBS for TFV-DP concentration. Longitudinal associations between missed doses and TFV-DP were examined using generalized estimating equations. Receiver operating characteristic (ROC) analyses evaluated the ability of SR to identify low TFV-DP in DBS (<699 fmol/punch). Logistic GEE models assessed the association between self-reported nonadherence and low TFV-DP. Results: Most participants were female (78%), median age 34 years (IQR, 27–42). Median TFV-DP concentrations declined with increasing self-reported missed doses: 1206 (IQR, 943–1442), 1009 (IQR, 773–1364), and 859 (IQR, 542–1194) fmol/punch for 0, 1–2, and ≥3 missed doses, respectively. Each additional missed dose was associated with lower TFV-DP concentrations in adjusted models (β = −29.2 fmol/punch per missed dose; p<0.001). Reporting ≥2 missed doses was associated with higher odds of low TFV-DP in longitudinal models (adjusted OR 1.50; p<0.001). Conclusions: Self-report missed doses correlated with TFV-DP concentrations over time but lacked sensitivity for detecting low drug exposure. Self-report remains pragmatic but may be optimized when paired with objective biomarkers to identify those at risk for treatment failure.
- 16 September 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
Longitudinal Performance of Self-Reported ART Adherence Compared With Tenofovir Diphosphate in Dried Blood Spots in South Africa
Background: Self-reported ART adherence is widely used in resource-limited settings but may not accurately reflect cumulative drug exposure. Few longitudinal studies in sub-Saharan Africa have directly compared self-report with pharmacologic adherence measures, specifically tenofovir diphosphate concentrations (TFV-DP) in dried blood spots (DBS). Setting: Observational cohort study conducted in four public-sector ART clinics in Cape Town, South Africa. Methods: We analyzed data from 250 adults living with HIV, followed monthly for 13 visits. Participants reported missed ART doses in the prior 30 days and provided DBS for TFV-DP concentration. Longitudinal associations between missed doses and TFV-DP were examined using generalized estimating equations. Receiver operating characteristic (ROC) analyses evaluated the ability of SR to identify low TFV-DP in DBS (<699 fmol/punch). Logistic GEE models assessed the association between self-reported nonadherence and low TFV-DP. Results: Most participants were female (78%), median age 34 years (IQR, 27–42). Median TFV-DP concentrations declined with increasing self-reported missed doses: 1206 (IQR, 943–1442), 1009 (IQR, 773–1364), and 859 (IQR, 542–1194) fmol/punch for 0, 1–2, and ≥3 missed doses, respectively. Each additional missed dose was associated with lower TFV-DP concentrations in adjusted models (β = −29.2 fmol/punch per missed dose; p<0.001). Reporting ≥2 missed doses was associated with higher odds of low TFV-DP in longitudinal models (adjusted OR 1.50; p<0.001). Conclusions: Self-report missed doses correlated with TFV-DP concentrations over time but lacked sensitivity for detecting low drug exposure. Self-report remains pragmatic but may be optimized when paired with objective biomarkers to identify those at risk for treatment failure.
- 11 September 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Effect of Pregnancy on Intracellular Tenofovir Diphosphate Exposure and Thresholds Following Oral Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis: A Directly Observed Dosing Study
Background: Intraerythrocytic tenofovir diphosphate (TFV-DP) concentrations from emtricitabine/tenofovir disoproxil fumarate (F/TDF) pre-exposure prophylaxis (PrEP) measured in dried blood spots (DBS) are approximately 30–40% lower during pregnancy, but data on TFV-DP concentrations in peripheral blood mononuclear cells (PBMCs) are limited. We evaluated the effect of pregnancy on intracellular TFV-DP concentrations in PBMCs. Methods: Directly observed dosing of daily oral F/TDF was administered to 18 healthy nonpregnant and 18 pregnant Kenyan women without HIV for 8 weeks. Blood for DBS and PBMC was collected weekly for nonpregnant and biweekly for pregnant women. TFV-DP concentrations in DBS and PBMCs were quantified using validated liquid chromatography-tandem mass spectrometry. Steady-state fitted TFV-DP concentrations in PBMC and DBS were compared between pregnant and nonpregnant women. Results: Median (IQR) age was 23 (20–27) years and gestational age was 16 (14–20) weeks for pregnant women at enrollment. Median (IQR) Cockroft Gault-estimated creatinine clearance was 131 (113–146) mL/min for nonpregnant versus 176 (154–196) mL/min for pregnant women. 1922 of 1925 (99.8%) expected doses were directly observed. Fitted steady-state median (IQR) TFV-DP concentrations in DBS were 1545 (1203, 1887) fmol/punch in nonpregnant versus 919 (835, 1003) fmol/punch in pregnant women [percent change: 40.5%, 95% CI (29.5%, 51.5%); P < .001]. Modeled steady-state geometric mean (GM) (95% CI) PBMC TFV-DP concentrations were 56.2 (48.0, 65.8) fmol/106 cells in nonpregnant versus 47.8 (40.4, 56.5) fmol/106 cells in pregnant women [GM ratio (95% CI): .85 (.68, 1.06); P = .15]. Conclusions: Steady-state TFV-DP concentrations in PBMCs were reassuringly not meaningfully different between pregnant and nonpregnant women.
- 11 September 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Effect of Pregnancy on Intracellular Tenofovir Diphosphate Exposure and Thresholds Following Oral Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis: A Directly Observed Dosing Study
Background: Intraerythrocytic tenofovir diphosphate (TFV-DP) concentrations from emtricitabine/tenofovir disoproxil fumarate (F/TDF) pre-exposure prophylaxis (PrEP) measured in dried blood spots (DBS) are approximately 30–40% lower during pregnancy, but data on TFV-DP concentrations in peripheral blood mononuclear cells (PBMCs) are limited. We evaluated the effect of pregnancy on intracellular TFV-DP concentrations in PBMCs. Methods: Directly observed dosing of daily oral F/TDF was administered to 18 healthy nonpregnant and 18 pregnant Kenyan women without HIV for 8 weeks. Blood for DBS and PBMC was collected weekly for nonpregnant and biweekly for pregnant women. TFV-DP concentrations in DBS and PBMCs were quantified using validated liquid chromatography-tandem mass spectrometry. Steady-state fitted TFV-DP concentrations in PBMC and DBS were compared between pregnant and nonpregnant women. Results: Median (IQR) age was 23 (20–27) years and gestational age was 16 (14–20) weeks for pregnant women at enrollment. Median (IQR) Cockroft Gault-estimated creatinine clearance was 131 (113–146) mL/min for nonpregnant versus 176 (154–196) mL/min for pregnant women. 1922 of 1925 (99.8%) expected doses were directly observed. Fitted steady-state median (IQR) TFV-DP concentrations in DBS were 1545 (1203, 1887) fmol/punch in nonpregnant versus 919 (835, 1003) fmol/punch in pregnant women [percent change: 40.5%, 95% CI (29.5%, 51.5%); P < .001]. Modeled steady-state geometric mean (GM) (95% CI) PBMC TFV-DP concentrations were 56.2 (48.0, 65.8) fmol/106 cells in nonpregnant versus 47.8 (40.4, 56.5) fmol/106 cells in pregnant women [GM ratio (95% CI): .85 (.68, 1.06); P = .15]. Conclusions: Steady-state TFV-DP concentrations in PBMCs were reassuringly not meaningfully different between pregnant and nonpregnant women.
- Open Access
- 3 September 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (9) , e70278
Predicting Oral HIV Pre‐Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum
Cisgender women face an increased risk of HIV acquisition during pregnancy and postpartum. Oral pre‐exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (F/TDF) is recommended in pregnancy despite limited published pharmacokinetic (PK) and efficacy data during pregnancy. Altered PK during pregnancy may reduce prophylactic efficacy and necessitate higher adherence. Tenofovir alafenamide (TAF) is a newer tenofovir prodrug with higher tenofovir diphosphate (TFV‐DP) exposure in peripheral blood mononuclear cells (PBMCs), but the prophylactic efficacy of F/TAF across different reproductive stages in women is understudied. We adapted a multiscale modeling framework to predict the prophylactic efficacy of F/TDF and F/TAF across varying adherence levels and during the second trimester, third trimester, and 6–12 weeks postpartum. Clinical trial simulations were conducted utilizing PBMC TFV‐DP and emtricitabine triphosphate concentrations as surrogate markers for F/TAF and F/TDF efficacy. For both F/TDF and F/TAF, prophylactic efficacy was lowest during the second trimester, increased in the third trimester (but remained below nonpregnant levels), and was highest postpartum. At high adherence levels of five or more pills per week, predicted effectiveness remained high across pregnancy and postpartum and effectiveness exceeded 97% for both regimens, with maximum decreases in the second trimester of only 0.9 percent point for F/TDF and 0.3 percent point for F/TAF. These findings suggest that adherence is the primary determinant of PrEP effectiveness during pregnancy and postpartum, while pregnancy‐related PK changes have a limited impact on efficacy.
- 3 September 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (9) , e70278
Open AccessPredicting Oral HIV Pre‐Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum
Cisgender women face an increased risk of HIV acquisition during pregnancy and postpartum. Oral pre‐exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (F/TDF) is recommended in pregnancy despite limited published pharmacokinetic (PK) and efficacy data during pregnancy. Altered PK during pregnancy may reduce prophylactic efficacy and necessitate higher adherence. Tenofovir alafenamide (TAF) is a newer tenofovir prodrug with higher tenofovir diphosphate (TFV‐DP) exposure in peripheral blood mononuclear cells (PBMCs), but the prophylactic efficacy of F/TAF across different reproductive stages in women is understudied. We adapted a multiscale modeling framework to predict the prophylactic efficacy of F/TDF and F/TAF across varying adherence levels and during the second trimester, third trimester, and 6–12 weeks postpartum. Clinical trial simulations were conducted utilizing PBMC TFV‐DP and emtricitabine triphosphate concentrations as surrogate markers for F/TAF and F/TDF efficacy. For both F/TDF and F/TAF, prophylactic efficacy was lowest during the second trimester, increased in the third trimester (but remained below nonpregnant levels), and was highest postpartum. At high adherence levels of five or more pills per week, predicted effectiveness remained high across pregnancy and postpartum and effectiveness exceeded 97% for both regimens, with maximum decreases in the second trimester of only 0.9 percent point for F/TDF and 0.3 percent point for F/TAF. These findings suggest that adherence is the primary determinant of PrEP effectiveness during pregnancy and postpartum, while pregnancy‐related PK changes have a limited impact on efficacy.
- Open Access
- 26 May 2026
- Published by Springer Nature in AIDS and Behavior
A Narrative Review of Remote Biospecimen Collection Product and Implementation Considerations for Sexual Health Clinical Research
Remote biospecimen collection (RBSC), such as home-based HIV testing and self-collection of dried blood spots (DBS) to assess adherence to antiretroviral drug regimens, has become an important tool to support clinical research because it can facilitate participant reach, lower participant burden, and reduce discomfort with attending research visits in clinic spaces. RBSC is common in sexual health clinical intervention trials to assess the impact of an intervention or program on primary and secondary outcomes. However, the products and strategies employed to successfully implement RBSC can vary widely across studies. The purpose of this narrative review is twofold. First, to provide an overview of currently available RBSC products, their attributes, and their suitability for various clinical research applications. Considerations for blood-based and volumetric absorptive microsampling collection products, as well as self-administered sexually transmitted infection testing and other specimen types, are described. Second, RBSC implementation considerations at each stage of the collection process are discussed primarily from the perspective of the authors' collective expertise and experience with RBSC in HIV prevention and treatment clinical research. Successful RBSC product selection and implementation require a multidisciplinary team approach that is participant-centered to achieve high return rates, and ample time should be allotted to address the complexities of the procedures and processes. This review of RBSC product and implementation considerations offers an actionable framework and roadmap when considering incorporation of RBSC into clinical trials research. TRIAL REGISTRATION: N/A.
- 26 May 2026
- Published by Springer Nature in AIDS and Behavior
Open AccessA Narrative Review of Remote Biospecimen Collection Product and Implementation Considerations for Sexual Health Clinical Research
Remote biospecimen collection (RBSC), such as home-based HIV testing and self-collection of dried blood spots (DBS) to assess adherence to antiretroviral drug regimens, has become an important tool to support clinical research because it can facilitate participant reach, lower participant burden, and reduce discomfort with attending research visits in clinic spaces. RBSC is common in sexual health clinical intervention trials to assess the impact of an intervention or program on primary and secondary outcomes. However, the products and strategies employed to successfully implement RBSC can vary widely across studies. The purpose of this narrative review is twofold. First, to provide an overview of currently available RBSC products, their attributes, and their suitability for various clinical research applications. Considerations for blood-based and volumetric absorptive microsampling collection products, as well as self-administered sexually transmitted infection testing and other specimen types, are described. Second, RBSC implementation considerations at each stage of the collection process are discussed primarily from the perspective of the authors' collective expertise and experience with RBSC in HIV prevention and treatment clinical research. Successful RBSC product selection and implementation require a multidisciplinary team approach that is participant-centered to achieve high return rates, and ample time should be allotted to address the complexities of the procedures and processes. This review of RBSC product and implementation considerations offers an actionable framework and roadmap when considering incorporation of RBSC into clinical trials research. TRIAL REGISTRATION: N/A.
- 1 April 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (4) , 424-431
The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in HIV-associated Tuberculosis
Background: Rifampicin reduces plasma tenofovir and intracellular tenofovir diphosphate (TFV-DP) concentrations when coadministered with tenofovir alafenamide fumarate (TAF). Standard-dose TAF with rifampicin still provided higher TFV-DP concentrations than tenofovir disoproxil fumarate (TDF) in a healthy volunteer study, but this interaction has not been assessed in people with HIV-associated tuberculosis. Setting: Open-label, three-period pharmacokinetic study in participants with HIV-1 on tenofovir-based ART (plus emtricitabine and efavirenz) in the maintenance phase of weight-based tuberculosis therapy. Methods: Concentrations of intracellular peripheral blood mononuclear cell TFV-DP and plasma tenofovir were measured during 3 treatment periods: (1) TDF 300 mg daily and rifampicin (TDF + RIF), (2) TAF 25 mg daily and rifampicin (TAF + RIF), and (3) TDF without rifampicin postcompletion of tuberculosis therapy (TDF–NoRIF). Twenty-four hour area under the concentration–time curves (AUC 0–24h ) were estimated, and geometric mean ratios (GMRs) with 95% confidence intervals were calculated to compare concentrations. Results: Eighteen participants were enrolled: median age of 42 years; 56% male. The TFV-DP AUC 0–24h GMRs comparing the TAF + RIF treatment period with the TDF + RIF and TDF–NoRIF periods were 5.46 (4.26–7.00) and 5.23 (3.71–7.37), respectively. Plasma tenofovir AUC 0–24h GMR was 0.08 (0.06–0.09) and 0.07 (0.06–0.09) when comparing TAF + RIF with the TDF + RIF and TDF–NoRIF periods, respectively. Conclusions: When combined with rifampicin, ART containing standard-dose TAF resulted in higher TFV-DP concentrations than TDF-based ART in participants with HIV-associated tuberculosis, supporting its use with rifampicin-containing tuberculosis therapy.
- 1 April 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (4) , 424-431
The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in HIV-associated Tuberculosis
Background: Rifampicin reduces plasma tenofovir and intracellular tenofovir diphosphate (TFV-DP) concentrations when coadministered with tenofovir alafenamide fumarate (TAF). Standard-dose TAF with rifampicin still provided higher TFV-DP concentrations than tenofovir disoproxil fumarate (TDF) in a healthy volunteer study, but this interaction has not been assessed in people with HIV-associated tuberculosis. Setting: Open-label, three-period pharmacokinetic study in participants with HIV-1 on tenofovir-based ART (plus emtricitabine and efavirenz) in the maintenance phase of weight-based tuberculosis therapy. Methods: Concentrations of intracellular peripheral blood mononuclear cell TFV-DP and plasma tenofovir were measured during 3 treatment periods: (1) TDF 300 mg daily and rifampicin (TDF + RIF), (2) TAF 25 mg daily and rifampicin (TAF + RIF), and (3) TDF without rifampicin postcompletion of tuberculosis therapy (TDF–NoRIF). Twenty-four hour area under the concentration–time curves (AUC 0–24h ) were estimated, and geometric mean ratios (GMRs) with 95% confidence intervals were calculated to compare concentrations. Results: Eighteen participants were enrolled: median age of 42 years; 56% male. The TFV-DP AUC 0–24h GMRs comparing the TAF + RIF treatment period with the TDF + RIF and TDF–NoRIF periods were 5.46 (4.26–7.00) and 5.23 (3.71–7.37), respectively. Plasma tenofovir AUC 0–24h GMR was 0.08 (0.06–0.09) and 0.07 (0.06–0.09) when comparing TAF + RIF with the TDF + RIF and TDF–NoRIF periods, respectively. Conclusions: When combined with rifampicin, ART containing standard-dose TAF resulted in higher TFV-DP concentrations than TDF-based ART in participants with HIV-associated tuberculosis, supporting its use with rifampicin-containing tuberculosis therapy.
- Open Access
An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics
Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) used for HIV treatment and pre-exposure prophylaxis have been proposed as gerotherapeutics based on their capacity to suppress age-associated retrotransposon activity. However, evidence in humans is currently lacking. Here we evaluated DNA methylation–based measures of biological aging in healthy people without HIV (aged 18–50) using samples from two separate randomized, directly observed dosing pharmacokinetic studies of FDA-approved NRTI regimens containing emtricitabine–tenofovir-alafenamide (FTC/TAF;200 mg/25 mg) or FTC-tenofovir-disoproxil fumarate (FTC/TDF; 200 mg/300 mg) for 12 weeks. In the FTC/TAF study (N=36), epigenetic aging measures based on DNA methylation (DNAm) profiling decreased over follow-up, including DunedinPACE (−0.061, p=0.019) and PhenoAge (−6.33, p=0.008), with concordant reductions (p<0.05) across additional systems-specific epigenetic clocks including those estimating brain aging. DNAm–based proxies of inflammatory biomarkers also declined, with significant reductions in epigenetic IL-6 (−0.058, p=0.029) and a trend toward reduced C-reactive protein (−0.231, p=0.059). In contrast, the FTC/TDF study (N=43) showed no significant changes across epigenetic clocks and proxies. These findings are consistent with TAF’s more favorable cellular pharmacology compared with TDF and support gerotherapeutic effects of FTC/TAF. Prospective placebo-controlled studies are warranted that integrate clinical pharmacology, direct transposable element readouts, and prespecified geroscience and DNA methylation–based aging endpoints.
Open AccessAn FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics
Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) used for HIV treatment and pre-exposure prophylaxis have been proposed as gerotherapeutics based on their capacity to suppress age-associated retrotransposon activity. However, evidence in humans is currently lacking. Here we evaluated DNA methylation–based measures of biological aging in healthy people without HIV (aged 18–50) using samples from two separate randomized, directly observed dosing pharmacokinetic studies of FDA-approved NRTI regimens containing emtricitabine–tenofovir-alafenamide (FTC/TAF;200 mg/25 mg) or FTC-tenofovir-disoproxil fumarate (FTC/TDF; 200 mg/300 mg) for 12 weeks. In the FTC/TAF study (N=36), epigenetic aging measures based on DNA methylation (DNAm) profiling decreased over follow-up, including DunedinPACE (−0.061, p=0.019) and PhenoAge (−6.33, p=0.008), with concordant reductions (p<0.05) across additional systems-specific epigenetic clocks including those estimating brain aging. DNAm–based proxies of inflammatory biomarkers also declined, with significant reductions in epigenetic IL-6 (−0.058, p=0.029) and a trend toward reduced C-reactive protein (−0.231, p=0.059). In contrast, the FTC/TDF study (N=43) showed no significant changes across epigenetic clocks and proxies. These findings are consistent with TAF’s more favorable cellular pharmacology compared with TDF and support gerotherapeutic effects of FTC/TAF. Prospective placebo-controlled studies are warranted that integrate clinical pharmacology, direct transposable element readouts, and prespecified geroscience and DNA methylation–based aging endpoints.
- 1 October 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 100 (2) , 162-169
Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment
Background: Intraerythrocytic tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in dried blood spots (DBS) have emerged as a gold-standard approach to assess adherence for oral preexposure prophylaxis (PrEP), but several considerations are important for proper interpretation. Methods: Key articles were reviewed related to use of intraerythrocytic TFV-DP and FTC-TP for adherence assessment including studies of pharmacokinetics, analytical methodologies, and application to a variety of PrEP settings. Important considerations were identified that influence TFV-DP and FTC-TP adherence interpretations by ≥15% and guidance was provided to assist when these considerations arise. Results: Factors identified included pregnancy status, specific drug interactions, hematocrit outside of 35%–50%, laboratory methodology, use of tenofovir alafenamide vs tenofovir disoproxil, whether DBS was collected before TFV-DP reaching steady state, and daily versus event-driven PrEP. Recommendations were provided in the form of adherence interpretation tables or mathematical adjustments to account for these considerations. Conclusions: Proper interpretation of TFV-DP and FTC-TP in DBS requires accounting for the factors identified above to maximize the value of these measurements.
- 1 October 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 100 (2) , 162-169
Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment
Background: Intraerythrocytic tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in dried blood spots (DBS) have emerged as a gold-standard approach to assess adherence for oral preexposure prophylaxis (PrEP), but several considerations are important for proper interpretation. Methods: Key articles were reviewed related to use of intraerythrocytic TFV-DP and FTC-TP for adherence assessment including studies of pharmacokinetics, analytical methodologies, and application to a variety of PrEP settings. Important considerations were identified that influence TFV-DP and FTC-TP adherence interpretations by ≥15% and guidance was provided to assist when these considerations arise. Results: Factors identified included pregnancy status, specific drug interactions, hematocrit outside of 35%–50%, laboratory methodology, use of tenofovir alafenamide vs tenofovir disoproxil, whether DBS was collected before TFV-DP reaching steady state, and daily versus event-driven PrEP. Recommendations were provided in the form of adherence interpretation tables or mathematical adjustments to account for these considerations. Conclusions: Proper interpretation of TFV-DP and FTC-TP in DBS requires accounting for the factors identified above to maximize the value of these measurements.
- 17 September 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women’s Interagency HIV Study Combined Cohort
Background: Tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) is an objective drug concentration measure which is predictive of future viremia in virally-suppressed persons with HIV (PWH) on TFV-based antiretroviral therapy (ART). Viral load (VL):TFV-DP mismatch (suppressed VL despite low TFV-DP concentrations) may increase future viremia risk. Previously, Black race, male sex, and higher body mass index were associated with lower TFV-DP concentrations among PWH receiving tenofovir disoproxil fumarate (TDF). The aim of this study was to assess mismatch rates in PWH on tenofovir alafenamide (TAF). Methods: DBS samples were obtained from Multicenter AIDS Cohort Study/Women’s Interagency HIV Study Combined Cohort participants receiving TAF-based ART for ≥3 months. Associations between pre-specified covariates and pharmacologic virologic mismatch (plasma VL <200 copies/mL and intracellular TFV-DP concentrations <1800 fmol/punches), were evaluated using logistic regression. Results: DBS was measured in 627 PWH (63% female) and median [IQR] age 55 [47-61] years. TFV-DP for VL 200 copies/mL was 2,375 [1,493-3,340] and 264 [13-949] fmol/punches, respectively. Females experienced 39% mismatch. Higher estimated glomerular filtration rate (eGFR; +15 mL/minute/1.73 m2), weight (+15 kg), and lower self-reported adherence (<95%) were associated with higher mismatch odds: 1.77 (1.40-2.28), 1.32 (1.11-1.57), and 5.12 (2.16-12.90), respectively. Males experienced 27% mismatch. Higher eGFR, weight, Black race, and lower adherence were associated with higher mismatch odds: 1.75 (1.22-2.62), 1.66 (1.19-2.39), 7.53 (2.87-22.28), and 9.61 (2.17-51.95), respectively. Conclusions: Weight, eGFR, self-reported adherence and Black race in males were associated with mismatch. These characteristics should be considered when designing adherence interventions.
- 17 September 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women’s Interagency HIV Study Combined Cohort
Background: Tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) is an objective drug concentration measure which is predictive of future viremia in virally-suppressed persons with HIV (PWH) on TFV-based antiretroviral therapy (ART). Viral load (VL):TFV-DP mismatch (suppressed VL despite low TFV-DP concentrations) may increase future viremia risk. Previously, Black race, male sex, and higher body mass index were associated with lower TFV-DP concentrations among PWH receiving tenofovir disoproxil fumarate (TDF). The aim of this study was to assess mismatch rates in PWH on tenofovir alafenamide (TAF). Methods: DBS samples were obtained from Multicenter AIDS Cohort Study/Women’s Interagency HIV Study Combined Cohort participants receiving TAF-based ART for ≥3 months. Associations between pre-specified covariates and pharmacologic virologic mismatch (plasma VL <200 copies/mL and intracellular TFV-DP concentrations <1800 fmol/punches), were evaluated using logistic regression. Results: DBS was measured in 627 PWH (63% female) and median [IQR] age 55 [47-61] years. TFV-DP for VL 200 copies/mL was 2,375 [1,493-3,340] and 264 [13-949] fmol/punches, respectively. Females experienced 39% mismatch. Higher estimated glomerular filtration rate (eGFR; +15 mL/minute/1.73 m2), weight (+15 kg), and lower self-reported adherence (<95%) were associated with higher mismatch odds: 1.77 (1.40-2.28), 1.32 (1.11-1.57), and 5.12 (2.16-12.90), respectively. Males experienced 27% mismatch. Higher eGFR, weight, Black race, and lower adherence were associated with higher mismatch odds: 1.75 (1.22-2.62), 1.66 (1.19-2.39), 7.53 (2.87-22.28), and 9.61 (2.17-51.95), respectively. Conclusions: Weight, eGFR, self-reported adherence and Black race in males were associated with mismatch. These characteristics should be considered when designing adherence interventions.